EGFR and neoplasm: However, as single agents, they have shown limited efficacy in EGFR‐mutated NSCLC, possibly due to low tumour mutational burden (TMB), lower PD‐L1 expression and an immunosuppressive tumour microenvironment (TME) in these patients.13, 14